Plasma thrombomodulin as a candidate biomarker for the diagnosis and prognosis of HBV-related acute-on-chronic liver failure
Xingping Zhou,Jinjin Luo,Xi Liang,Peng Li,Keke Ren,Dongyan Shi,Jiaojiao Xin,Jing Jiang,Jiaxian Chen,Lulu He,Hui Yang,Shiwen Ma,Bingqi Li,Jun Li
DOI: https://doi.org/10.2147/idr.s437926
2024-03-27
Infection and Drug Resistance
Abstract:Xingping Zhou, 1, &ast Jinjin Luo, 1, &ast Xi Liang, 1, 2 Peng Li, 1 Keke Ren, 1 Dongyan Shi, 1, 2 Jiaojiao Xin, 1, 2 Jing Jiang, 1, 2 Jiaxian Chen, 1 Lulu He, 1 Hui Yang, 1 Shiwen Ma, 1 Bingqi Li, 1 Jun Li 1, 2 1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China; 2 Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun Li, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's Republic of China, Tel/Fax +86-571-87236425, Email Background and Aim: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a complicated syndrome with high short-term mortality. Effective biomarkers are required for its early diagnosis and prognosis. This study aimed to determine the diagnostic and prognostic value of thrombomodulin (TM) in patients with HBV-ACLF. Methods: The expression of TM during disease progression was evaluated through transcriptomics analysis. The plasma TM concentrations of 393 subjects with HBV-ACLF (n=213), acute-on-chronic hepatic dysfunction (ACHD, n=50), liver cirrhosis (LC, n=50) or chronic hepatitis B (CHB, n=50), and normal controls (NC, n=30) from a prospective multicenter cohort, were measured to verify the diagnostic and prognostic significance of plasma TM for HBV-ACLF patients by enzyme-linked immunosorbent assay (ELISA). Results: TM mRNA was highly expressed in the HBV-ACLF group compared with the ACHD group (AUROC=0.710). High expression of TM predicted poor prognosis for HBV-ACLF patients at 28/90 days (AUROCs=0.823/0.788). Functional analysis showed that TM was significantly associated with complement activation and the inflammatory signaling pathway. External validation confirmed its high diagnostic accuracy for HBV-ACLF patients (AUROC=0.796). Plasma TM concentrations were correlated with organ failure, including coagulation and kidney failure. Plasma TM concentrations showed a potential prognostic value for 28-day mortality rates (AUROC=0.702). Risk stratification specifically identified HBV-ACLF patients with a high risk of death as having a plasma TM concentration of ≥ 8.4 ng/mL. Conclusion: This study reveals that the plasma TM can be a candidate biomarker for early diagnosis and prognosis of HBV-ACLF, and might play a vital role in coagulation and inflammation. Keywords: thrombomodulin, HBV-ACLF, biomarker, organ failure Acute-on-chronic liver failure (ACLF) is generally regarded as a complex clinical syndrome characterized by acute decompensation of liver function and multiple organ failure in patients suffering from chronic liver disease. 1 The pathologic features and etiology of ACLF patients differ with regional distribution. 2 Our previous study showed that the clinical characteristics of patients with hepatitis B virus-related ACLF (HBV-ACLF) were significantly different from those of alcoholic hepatitis-related ACLF patients in Western countries. 3 HBV-ACLF may progress fast, with a short-term mortality rate of 50% ~ 90%, even with the most intensive treatment. 3,4 Therefore, to guide concise clinical decisions, to improve management, and to minimize futile and expensive care, insight into effective biomarkers for the early diagnosis and prognosis of patients with HBV-ACLF is imperative. Thrombomodulin (TM), a transmembrane glycoprotein receptor, is specifically expressed on endothelial cells' surface to bind thrombin and activate protein C. This facilitates the degradation of coagulation factors Va and VIIIa, reducing thrombin production. 5 Soluble TM is a reliable biomarker for indicating endothelial cell injury. 6 Liver sinusoidal endothelial cells (LSECs) participate in liver angiogenesis. During the progression of liver disease, soluble TM protein is released into blood due to the injury -Abstract Truncated-
pharmacology & pharmacy,infectious diseases